In this context, the specific inhibition of the overactive SHH-signaling pathway by SHH-inhibitors (i.e. FDA-approved vismodegib and sonicdegib75) early during disease progression, thereby minimizing mitochondrial dysfunction, might become an attractive therapeutic option for halting or slowing down sPD progression. The gene discussed is SHH; the disease is Platelet storage pool disease.